Resultats de la cerca - Ravi Shankar Prasad Singh
- Mostrar 1 - 7 resultats de 7
-
1
-
2
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascend... per Spencer I. Danto, Negin Shojaee, Ravi Shankar Prasad Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan, Iain Kilty
Publicat 2019Artigo -
3
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomiz... per Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan, Erika Roberts, Sanela Tarabar, Elena Peeva, Michael S. Vincent, Jeremy D. Gale
Publicat 2022Artigo -
4
Why airborne transmission hasn't been conclusive in case of COVID-19? An atmospheric science perspective per Kirpa Ram, Roseline C. Thakur, Dharmendra Kumar Singh, Kimitaka Kawamura, Akito Shimouchi, Yoshika Sekine, Hidekazu Nishimura, Sunit K. Singh, Chandra Mouli Pavuluri, Ravi Shankar Prasad Singh, S. N. Tripathi
Publicat 2021Revisão -
5
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans per Heather Eng, Alyssa Dantonio, Eugene P. Kadar, R. Scott Obach, Li Di, Jian Lin, Nandini C. Patel, Britton Boras, Gregory S. Walker, Jonathan J. Novak, Emi Kimoto, Ravi Shankar Prasad Singh, Amit S. Kalgutkar
Publicat 2022Artigo -
6
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir per Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman, Phylinda L. Chan, Rohit Rao, Richard Allen, Lien Van Eyck, Sylvester Pawlak, Eugene P. Kadar, Frances Clark, Haihong Shi, Annaliesa S. Anderson, Michael Binks, Sandeep Menon, Gianluca Nucci, Arthur Bergman
Publicat 2022Artigo -
7
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19 per Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Rose Ann Ferre, K.S. Gajiwala, Scott Gibson, S.E. Greasley, Brett L. Hurst, Eugene P. Kadar, Amit S. Kalgutkar, Jack C. Lee, Jisun Lee, Wei Liu, Stephen W. Mason, Stephen Noell, Jonathan J. Novak, R. Scott Obach, Kevin Ogilvie, Nandini C. Patel, Martin Pettersson, K. Devendra, Matthew R. Reese, M. F. Sammons, Jean G. Sathish, Ravi Shankar Prasad Singh, Claire M. Steppan, Al Stewart, Jamison B. Tuttle, Lawrence W. Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu
Publicat 2021Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Pharmacology
Adverse effect
Antiretroviral therapy
Viral load
Chemistry
Pharmacokinetics
Ritonavir
Virus
Bioavailability
Biochemistry
Biology
Clinical trial
Coronavirus disease 2019 (COVID-19)
Disease
Drug
Immunology
Infectious disease (medical specialty)
Pathology
Protease inhibitor (pharmacology)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Tolerability
Virology
Airborne transmission
Alternative medicine
Atmosphere (unit)
Atmospheric sciences
Biotechnology
CYP3A4